This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.

Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) announced a services agreement with Nanosoft Polymers to support development of ONC010, the company’s lead nanoparticle-formulated PNKP inhibitor. Under the agreement, Nanosoft will provide polymer process development, analytical characterization, formulation optimization, scale-up support and technology transfer services for Onco’s proprietary PEO-PBCL polymer platform as the program advances through IND-enabling development and preparation for future clinical studies.

The collaboration is intended to strengthen the manufacturing and formulation foundation of ONC010 by establishing scalable polymer production processes, enhancing analytical methods and supporting future GMP manufacturing readiness. Nanosoft’s work will complement ongoing chemistry, manufacturing and controls activities with Dalton Pharma Services and preclinical development efforts at Nucro-Technics as Onco advances ONC010 toward first-in-human clinical evaluation.

To view the full press release, visit https://ibn.fm/djEgt

About Onco-Innovations Limited

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The Company has secured an exclusive worldwide license to patented technology that targets solid tumours.

NOTE TO INVESTORS: The latest news and updates relating to ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

This contant was orignally distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is InvestorNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Engages Nanosoft to Advance ONC010 Development Program.